Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 12151396
Maekawa M, Nishida E, Tanoue T (2002) Identification of the Anti-proliferative protein Tob as a MAPK substrate. J Biol Chem 277, 37783-7 12151396
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S152-p - TOB1 (human)
Modsite: PASSVSSsPsPPFGH SwissProt Entrez-Gene
Orthologous residues
TOB1 (human): S152‑p, TOB1 (mouse): S152‑p
Characterization
Methods used to characterize site in vivo mutation of modification site
Relevant cell lines - cell types - tissues:  3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout]
Cellular systems studied:  cell lines
Species studied:  mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE JNK2 (human)
KINASE ERK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase
U0126 FGF1 inhibit treatment-induced increase
EGF increase
U0126 EGF inhibit treatment-induced increase
serum increase
U0126 serum inhibit treatment-induced increase
PDGF increase
estradiol increase
Downstream Regulation
Effect of modification (function):  activity, inhibited
Effect of modification (process):  cell cycle regulation
Comments:  the antiproliferative function of TOB1 is inhibited by phosphorylation.

S154-p - TOB1 (human)
Modsite: SSVSSsPsPPFGHSA SwissProt Entrez-Gene
Orthologous residues
TOB1 (human): S154‑p, TOB1 (mouse): S154‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site
Relevant cell lines - cell types - tissues:  3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], C2C12 (myoblast), COS (fibroblast)
Cellular systems studied:  cell lines
Species studied:  green monkey, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
KINASE JNK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase
U0126 FGF1 inhibit treatment-induced increase
EGF increase
U0126 EGF inhibit treatment-induced increase
serum increase
U0126 serum inhibit treatment-induced increase
PDGF increase
estradiol increase
Downstream Regulation
Effect of modification (function):  activity, inhibited
Effect of modification (process):  cell cycle regulation
Comments:  the antiproliferative function of TOB1 is inhibited by phosphorylation.

S164-p - TOB1 (human)
Modsite: FGHSAAVsPTFMPRS SwissProt Entrez-Gene
Orthologous residues
TOB1 (human): S164‑p, TOB1 (mouse): S164‑p
Characterization
Methods used to characterize site in vivo mutation of modification site
Relevant cell lines - cell types - tissues:  3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout]
Cellular systems studied:  cell lines
Species studied:  mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
KINASE JNK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase
U0126 FGF1 inhibit treatment-induced increase
EGF increase
U0126 EGF inhibit treatment-induced increase
serum increase
U0126 serum inhibit treatment-induced increase
PDGF increase
estradiol increase
Downstream Regulation
Effect of modification (function):  activity, inhibited
Effect of modification (process):  cell cycle regulation
Comments:  the antiproliferative function of TOB1 is inhibited by phosphorylation.